CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics' (CTMX) quarterly Long-Term Deferred Tax came in at $87.6 million in Q4 2018.

CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018) Analysis & Trends

CytomX Therapeutics (CTMX) has 1 years of Long-Term Deferred Tax data on file, last reported at $87.6 million in Q4 2018.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $87.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $87.6 million (changed N/A YoY) and the FY2018 annual result came in at $87.6 million, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $87.6 million in Q4 2018.
In the past five years, Long-Term Deferred Tax ranged from a high of $87.6 million in Q4 2018 to a low of $87.6 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytomX Therapeutics	732.14 Mn	401.86 Mn	-

Download Data

Date	Value
Dec 31, 2018	87.60 Mn